and efficacy of Nemluvio in moderate-to-severe prurigo nodularis.1Results showed that Nemluvio maintained long-term disease control and a well-tolerated safety profile, with clinically meaningful improvements in itch intensity, skin lesions and quality of life up to three years.1Results will be presented at 2026 Winter Clinical Miami and build on previous data from OLYMPIA – the largest completed pivotal clinical program in prurigo nodularis and the only one with a LTE study.1,6,7








“Prurigo nodularis is not only intensely itchy, painful and uncomfortable, it can also take a profound toll on sleep, emotional wellbeing, and daily functioning. That’s why achieving sustained, long-term disease control is critical for patients. These data show that Nemluvio can make a meaningful difference to people’s lives by improving itch, skin lesions and quality of life up to three years, with a well-tol
=*=*=*=*=*=
当前为第2/12页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页